The Journal of Urology · 1997 · 52 citations · 11 references
MedicinePathologyUrologyCytopathologyGenitourinary OncologyUrologic OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerUrinary CytologyUrologic Cancer DiagnosisUrothelial CarcinomaBladder Cancer CytologyBladder Cancer DiagnosisUrine Cytology MarkersUrine-based Cancer DetectionUrothelial Carcinoma Cytology
PURPOSE: CYFRA 21-1, an immunoradiometric assay developed for the detection of a soluble cytokeratin 19 fragment, is evaluated for its diagnostic performance in urine of patients with transitional cell carcinoma. MATERIALS AND METHODS: CYFRA 21-1 was investigated in serum and urine of 128 patients, including 48 with bladder transitional cell carcinoma (group 1), 44 with other urological pathological conditions (group 2) and 36 free of urothelial disease (group 3). Urinary cytopathology was also performed. RESULTS: Mean urinary CYFRA was 123.5 +/- 53, 11.9 +/- 4.8 and 2.3 +/- 0.2 ng./ml. for groups 1 to 3, respectively, and was significantly different. From the receiver operating characteristics curve, the optimal combination of 96% sensitivity and 74% specificity was determined for a threshold value of 4 ng./ml. while overall cytopathology sensitivity was 43%. CONCLUSIONS: Urinary CYFRA 21-1 may be a useful marker for diagnosing transitional cell carcinoma.
11